INTRODUCTION
Actinomycete secondary metabolism is under the delicate and complicated regulation by a producing organism. Particularly important factors include physiological aspects such as primary metabolism and morphological differentiation, and gross production balance among the secondary metabolites. Comprehensive understanding of secondary metabolism apparently requires the intensive study of a model metabolite produced by a genetically well-characterized strain. Streptomyces coelicolor A3(2), the most genetically characterized streptomycete with a complete genome sequence 1) , produces at least four metabolically distinct antibiotics. One of the antibiotics, actinorhodin (ACT), has served as one of the model compounds for studying a type II polyketide synthase (PKS). Polyketides (PKs) are the components of a vast variety of microbial and plant secondary metabolites, including biologically active compounds such as antibiotics. The structural variety of PKs is given by the options in choice of starter/extending units, number of condensations, and degree of subsequent reductive cycles, all of which being conferred by PKS and closely related enzymes. Subsequent post-PKS tailoring steps provide the final product with further structural variations. Critical structural elements for biological activities in valuable antibiotics are derived from tailoring steps, of which stereochemical control and glycosylation are particularly important in PK antibiotics. Biosynthetic studies on ACT and structurally related benzoisochromanequinone (BIQ) antibiotics have been carried out in our laboratory in conjunction with the on-going comprehensive studies on a model actinomycete, S. coeliclor A3(2). We have also been engaged in metabolic engineering of deoxysugar moieties of polyktide glycosides, focusing on urdamycins (URDs) from Streptomyces fradiae Tü2717, since URDs contains ideal model deoxysugars (D-olivose and L-rhodinose) attached via C-and O-glyosylations. This article surveys our work on the BIQs and URDs.
Cloning of the BIQ biosynthetic gene cluster towards comparative analysis
My research on the biosynthesis of the BIQs started in 1994, when the sequencing of the whole biosynthetic gene cluster of ACT (the act cluster) had come to the final stage in the groups of Hopwood and Malpartida 2) . The complete sequence of the act cluster became one of the first examples of the cloning and sequencing of the entire biosynthetic cluster of a PK antibiotic, revealing the size of the cluster (22 kb) and the existence of 22 open reading frames (ORFs) 3) . A number of aromatic PKS biosynthetic genes were characterized using the act PKS genes as hybridization probes. Apart from the act cluster, type II PKS genes cloned and sequenced from BIQ-producers by early 1994 were for granaticin (GRA, the gra cluster) 4) , frenolicin B (the fren cluster) 5) , and griseusin B (the gris cluster) 6) ( Fig. 1 ). BIQs present a number of interesting biosynthetic problems concerning post-PKS tailoring steps including cyclizations (condensations), oxido-reductions, dehydrations, rearrangements, and group transfers 7) . They should proceed in a regio-and stereo-specific manner by the responsible enzymes encoded by a given biosynthetic gene cluster. We made some functional assignments of the act tailoring gene products based on their significant similarities with other known proteins, and proposed a biosynthetic scheme to the BIQ crhomophore 2) . It was also realized that there exist some cluster genes whose deduced functions are unavailable from database searches (the 'unknown'). That led us attempt to clone and characterize further complete BIQ biosynthetic gene clusters towards comparative and comprehensive study. The target BIQs were GRA and medermycin (MED), both possess C-glycosylated deoxysugar moieties, and opposite trans stereochemistry at C-3 and C-15 on the pyran ring. The gra cluster from Streptomyces violaceoruber Tü22 was cloned on a cosmid, and expressed in the heterologous host, S. coelicolor CH999 to produce GRA, probing the clone completeness 8) . The key technique was screening of a genomic library with the dual probes for PKS and a common enzyme for deoxysugar biosynthesis, an NDP-glucose-4,6-dehydratase 9) . Analysis of the complete 39, 250 bp of the insert revealed 37 complete ORFs. Similar strategy was applied to the cloning of a 36,202-bp genetic segment consisting of 34 complete ORFs from Streptomyces sp. AM-7161, covering the whole MED biosynthetic genes (the med cluster) 10) . Functional assignment of the deduced products was made for PKS and biosynthetically related enzymes, tailoring steps including strereochemical control, oxidation, deoxysugar pathway, C-glycosylation, and regulation. The gra and med cluster was estimated to be about 32kb (32 ORFs) and 30 kb (29 ORFs), respectively ( Fig. 2) .
Comparison among the three complete BIQ gene clusters revealed some common 'unknown' genes. An example is actVI-ORF3 (med-ORF5 and gra-ORF18 are the homologues), which was highlighted by a recent proteomic analysis of Streptomyces coelicolor A3(2) 11) .
Functional analysis of the actVI genes involved in ACT biosynthesis
The actVI region was deduced to be involved in pyran ring formation under stereochemical control based on the fact that the two actVI mutants 12) produce aloesaponarin II as a shunt product 13) . ACT has a unique dimeric structure with connection of two BIQ chromophores by a C-C bond. Its pH indicator properties (red under acidic conditions and blue under basic ones) provide a convenient method of ACT detection simply by blue pigmentation. The actVI region (5.7 kb) revealed six ORFs, ORFB, ORFA, ORF1, ORF2, ORF3, and ORF4. Subsequent gene disruption of each ORF gave the following phenotypes: (a) disruption of ORFB and ORF4 did not prevent blue pigmentation; (b) the ORFA-disruptant showed an obvious reduction in blue pigmentation; (c) brownish pigment was produced by the disruptants of ORF1 and ORF2; (d) the ORF3-disruptant produced a reddish pigment which became yellowish and later turned blue on ammonia fuming. For detailed functional analysis of the actVI genes, metabolites of each disruptant were chemically characterized by a newly devised method of ACT detection with a combination of HPLC and LC/MS 14) . ACT was produced by those of ORFB, ORFA, ORF3, and ORF4. Instead of ACT, the ORF1 disruptant produced 3,8-dihydroxy-1-methylanthraquinone-2-carboxylic acid (DMAC) and aloesaponarin II as shunt products. The ORF2 disruptant gave 4,10-dihydro-9-hydroxy-1-methyl-10-oxo-3H-naphtho[2,3-c]pyran-3-(S)-acetic acid, (S)-DNPA, previously shown to be an ACT biosynthetic intermediate 15) . These results support our previous proposal for stereospecific pyran ring formation in the biosynthesis of ACT, most importantly suggesting that the actVI-ORF2 product would recognize (S)-DNPA as a substrate for stereospecific reduction at C-15.
Disruption of ORFA led not only to significant reduction in ACT production, but also to production of an unknown compound X, together with (S)-DNPA. Its structure was elucidated as 1,4-naphthoquinone-8-hydroxy-3-[3(S)-acetoxy-butyric acid], (S)-NHAB, based on NMR, MS, and CD spectroscopic data as well as a single crystal X-ray crystallographic analysis 16, 17) . The formation of (S)-NHAB involves a retro-Claisen type C-C bond cleavage of an ACT biosynthetic intermediate (Fig. 3) . Feeding experiments with [1-13 C] and [2-13 C] acetates indicated its biosynthetic origin as a single octaketide chain. The relevant gene product, Act-ORFA, which is a functionally unknown protein, is proposed to play a regulatory role related to the multi-enzymatic steps to ACT production, based on the metabolic profile of its disruptant and the wide distribution of actVI-ORFA homologues in the gene clusters for Streptomyces aromatic PKSs.
Functional analysis of the genes involved in the stereochemical control in BIQ biosynthesis
The BIQs all show a trans configuration in respect of the C-3 and C-15 chiral centers, which are either (3S, 15R) or (3R, 15S). ACT represents the former type, and the opposite stereochemistry is exemplified by GRA (Fig. 1) .
The common bicyclic intermediate (Fig. 3 ) was postulated to undergo stereospecific reduction to provide either the 3-(S) or the 3-(R) configuration of DNPA. In ACT biosynthesis, actVI-ORF1 was proven 18) to encode a dedicated reductase (RED1) to establish the (S)-configuration at C-3, by the co-expression of actVI-ORF1 with the early ACT biosynthetic genes to produce (S)-DNPA. An obvious expectation was the existence of an actVI-ORF1 homologue, encoding a reductase (RED2) with the opposite stereospecificity to produce (R)-DNPA, in the gra cluster. However, there is no apparent candidate amongst the ORFs characterized 8) in the entire cluster. The gra cluster instead was found to contain five ORFs, gra-ORF5, 6, 17, 22 and 26, likely to encode ketoreductases. We then demonstrated 19) that gra-ORF5 and -ORF6 restore blue pigmentation characteristic of the ACT chromophore to the S. coelicolor B22 mutant which is functionally deficient in actVI-ORF1, indicating the production of ACTlike products with possible pyran ring formation under unnatural stereochemical control at C-3. Functional analysis based on the co-expression system above was applied to combinations of the four ketoreductase genes, actIII, actVI-ORF1, gra-ORF5, and gra-ORF6. gra-ORF6 was essential to produce (R)-DNPA in GRA biosynthesis 20) . Database analysis suggested that the gra-ORF6 product, a putative short-chain dehydrogenase, has virtually no sequence homology with the actVI-ORF1 protein. This demonstrates a new example of opposite stereochemical control in antibiotic biosynthesis, providing a key branch point to afford diverse chiral metabolic pools.
The bicyclic intermediate itself is unable to be isolated from any act mutants because of its spontaneous formation of the shunt products, DMAC and aloesaponarin II. Further biochemical study of RED1/2 such as in vitro characterization requires a suitable analogous substrate. A series of unnatural b-keto-esters were subjected to biotransformations using S. coelicolor strain carrying combinations of ketoreducatase genes. Enantioselective reductions occurred in the recombinant carrying RED1. The structurally closer analogue gave enantiopure (S)-product, rigorously confirming that the actVI-ORF1 protein functions as stereospecific reductase at C-3 in ACT biosynthesis 21) .
Metabolic engineering of the deoxysugar genes involved in URD biosynthesis
URDs produced by S. fradiae Tü2717 are a class of angucycline antibiotics. The principal compound, urdamycin A (URD-A), bears trisaccharide unit (Dolivose-L-rhodinose-D-olivose) attached C-glycosidically to the polyketide aglycone at C-9, and single L-rhodinose as O-glycoside at C-12b ( Fig. 4) . A 30-kb genomic region of S. fradiae Tü2717 carries the URD biosynthetic gene cluser (the urd cluster), including the genes for the deoxysugar-forming enzymes, UrdG, UrdH, UrdS, UrdT, UrdQ, UrdZ1, and UrdZ3. Their deduced functions allowed us to assign the gene functions to each of the biosynthetic steps at D-olivose and L-rhodinose derived from D-glucose-1phosphate, branching at the stage of NDP-4-ketoglucose-2,6-dideoxy-D-glucose which is converted either to NDP-D-olivose by Urd-R or to NDP-L-rhodinose by UrdQ, UrdZ1, and UrdZ3 22) . Metabolic engineering of the urd deoxysugar genes were conducted in collaboration with Bechthold's laboratory. Inactivation of urdR, encoding NDP-hexose-4-keto reducatase, led to the formation of the novel URD M which carries D-rhodinose, C-glycosidically attached at C-9 22) .
The urd cluster provides four glycosyltransferase (GT) genes, urdGT1a, urdGT1b, urdGT1c, and urdGT2, each of which was assigned to a specific GT reaction in URD-A biosynthesis. Particularly interesting are urdGT1b and urdGT2, since they are strikingly similar (91% identity at the amino acid level) despite of their distinct transferase functions of D-rhodinose (UrdGT1c) and D-olivose (UrdGT1b). They also possess regio-and mechanistic specificities: α-(1,3)-glycosylation for UrdGT1c; β-(1,4)glycosylation for UrdGT1b. A series of their chimeric GT genes were constructed, and expressed in S. fradiae mutants lacking GT1b/GT1c activity to find the region determining the substrate specificities. A 31-amino acid region close to the N-terminus, which differs 18 amino acids, was identified to control both sugar and acceptor specificities 23) . Metabolic engineering to the region, including DNA shuffling, gave rise to the novel GT specificities leading to unnatural URD derivatives, including URD-P possessing a branched trisaccahradide chain 24, 25) . Fig. 4 . Biosynthetic overview of urdamycinA in S. fradiae.
